- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.08. | Novo strikes RNA drug deal with startup Replicate | ||
| 27.08. | FDA approves updated COVID boosters, but narrows use | ||
| 27.08. | Lilly says breast cancer drug extended survival in study | ||
| 27.08. | Amylyx drug comes up short; Sanofi names new CMO | ||
| 27.08. | Startup Wugen raises $115M for 'off-the-shelf' CAR-T | ||
| 26.08. | Lilly to submit obesity pill after hitting goal in third late-stage trial | ||
| 26.08. | Why an FDA decision on Stealth's Barth drug could ripple through the rare disease field | ||
| 26.08. | RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial | ||
| 25.08. | Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales | ||
| 25.08. | FDA suspends license for Valneva's chikungunya shot | ||
| 25.08. | AbbVie wagers more than $1B on Gilgamesh's psychedelic drug | ||
| 25.08. | Drugs from China are reshaping biotech. Track the licensing deals here. | ||
| 22.08. | FDA cancels adcomm on Biohaven drug; Catalent lays off staff | ||
| 21.08. | US, EU agree to terms of framework trade pact | ||
| 21.08. | FDA approves Ionis' hereditary angioedema drug | ||
| 21.08. | Gilead dives into 'in vivo' cell therapy with $350M buyout of Interius | ||
| 21.08. | Sarepta pushes off debt payments in bid to regain financial footing | ||
| 20.08. | Xoma, a drug royalty specialist, buys another 'zombie' biotech | ||
| 20.08. | Lilly searching for new neuro chief as White set to retire | ||
| 20.08. | Rocket can resume gene therapy trial after FDA lifts hold | ||
| 20.08. | MAHA may take aim at pharma DTC ads | ||
| 19.08. | Viking shares sink as obesity pill misses expectations in key study | ||
| 19.08. | CSL to separate vaccine business, cut jobs | ||
| 19.08. | PTC Therapeutics drug for Friedrich's ataxia rejected; Lilly sells nearly $7B in bonds | ||
| 19.08. | Omega's Otello Stampacchia on the 'reset' changing biotech for the better |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .